Particularly, the anti-PCSK9 agents under development are mainly focused on the blood lipid metabolism; however, no studies have been conducted to investigate the treatment efficiency of these agents in the setting of bacterial infection and sepsis. The gene discussed is PCSK9; the disease is bacterial infectious disease.